Is Neurogene Stock a Good Investment?
Neurogene Investment Advice | NGNE |
- Examine Neurogene's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Neurogene's leadership team and their track record. Good management can help Neurogene navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceutical Products space and any emerging trends that could impact Neurogene's business and its evolving consumer preferences.
- Compare Neurogene's performance and market position to its competitors. Analyze how Neurogene is positioned in terms of product offerings, innovation, and market share.
- Check if Neurogene pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Neurogene's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Neurogene stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Neurogene is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Neurogene Stock
Researching Neurogene's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 89.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.82. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Neurogene recorded a loss per share of 3.66. The entity had not issued any dividends in recent years. The firm had 1:4 split on the 19th of December 2023.
To determine if Neurogene is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Neurogene's research are outlined below:
| Neurogene generated a negative expected return over the last 90 days | |
| Neurogene has high historical volatility and very poor performance | |
| Net Loss for the year was (36.32 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Neurogene generates negative cash flow from operations | |
| Over 89.0% of the company shares are owned by institutional investors |
Neurogene uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Neurogene. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Neurogene's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 19th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 19th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Neurogene's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 593.14 M.Basic technical analysis of Neurogene Stock
As of the 20th of March, Neurogene secures the Standard Deviation of 4.85, risk adjusted performance of (0.09), and Mean Deviation of 3.5. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Neurogene, as well as the relationship between them. Please verify Neurogene market risk adjusted performance, variance, as well as the relationship between the Variance and value at risk to decide if Neurogene is priced some-what accurately, providing market reflects its recent price of 15.18 per share. Given that Neurogene has information ratio of (0.09), we recommend you to check Neurogene's last-minute market performance to make sure the company can sustain itself at a future point.Neurogene's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Neurogene insiders, such as employees or executives, is commonly permitted as long as it does not rely on Neurogene's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Neurogene insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cvijic Christine Mikail over a month ago Acquisition by Cvijic Christine Mikail of 53900 shares of Neurogene at 36.06 subject to Rule 16b-3 | ||
Rachel McMinn over three months ago Acquisition by Rachel McMinn of 47500 shares of Neurogene at 20.4 subject to Rule 16b-3 | ||
Noonberg Sarah B. over three months ago Acquisition by Noonberg Sarah B. of 7700 shares of Neurogene at 42.59 subject to Rule 16b-3 | ||
Freedland Cory S. over six months ago Acquisition by Freedland Cory S. of 7700 shares of Neurogene at 42.59 subject to Rule 16b-3 | ||
Baker Bros. Advisors Lp over six months ago Acquisition by Baker Bros. Advisors Lp of 28782 shares of Neurogene subject to Rule 16b-3 | ||
Stuart Cobb over a year ago Acquisition by Stuart Cobb of 20391 shares of Neurogene subject to Rule 16b-3 | ||
Vance Holly over a year ago Acquisition by Vance Holly of 100000 shares of Neurogene subject to Rule 16b-3 | ||
Woods Robert Keith over a year ago Acquisition by Woods Robert Keith of 15400 shares of Neurogene subject to Rule 16b-3 |
Neurogene's Outstanding Corporate Bonds
Neurogene issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Neurogene uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Neurogene bonds can be classified according to their maturity, which is the date when Neurogene has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand Neurogene's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Neurogene's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | 1.98 | |||
| Mean Deviation | 3.5 | |||
| Coefficient Of Variation | (926.32) | |||
| Standard Deviation | 4.85 | |||
| Variance | 23.56 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.55) | |||
| Total Risk Alpha | (0.12) | |||
| Treynor Ratio | 1.97 | |||
| Maximum Drawdown | 31.27 | |||
| Value At Risk | (7.67) | |||
| Potential Upside | 6.54 | |||
| Skewness | 0.8628 | |||
| Kurtosis | 3.61 |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | 1.98 | |||
| Mean Deviation | 3.5 | |||
| Coefficient Of Variation | (926.32) | |||
| Standard Deviation | 4.85 | |||
| Variance | 23.56 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.55) | |||
| Total Risk Alpha | (0.12) | |||
| Treynor Ratio | 1.97 | |||
| Maximum Drawdown | 31.27 | |||
| Value At Risk | (7.67) | |||
| Potential Upside | 6.54 | |||
| Skewness | 0.8628 | |||
| Kurtosis | 3.61 |
Consider Neurogene's intraday indicators
Neurogene intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Neurogene stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Neurogene time-series forecasting models is one of many Neurogene's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Neurogene's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Neurogene Stock media impact
Far too much social signal, news, headlines, and media speculation about Neurogene that are available to investors today. That information is available publicly through Neurogene media outlets and privately through word of mouth or via Neurogene internal channels. However, regardless of the origin, that massive amount of Neurogene data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Neurogene news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Neurogene relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Neurogene's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Neurogene alpha.
Neurogene Corporate Management
| MD MBA | Senior Development | Profile | |
| Effie MD | Senior Research | Profile | |
| Donna JD | Senior Counsel | Profile | |
| CPI FAAP | Quality Affairs | Profile | |
| Ricardo Jimenez | Senior Operations | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Neurogene Stock refer to our How to Trade Neurogene Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurogene. If investors know Neurogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Neurogene is measured differently than its book value, which is the value of Neurogene that is recorded on the company's balance sheet. Investors also form their own opinion of Neurogene's value that differs from its market value or its book value, called intrinsic value, which is Neurogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurogene's market value can be influenced by many factors that don't directly affect Neurogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Neurogene's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Neurogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.